Conference Paper

Hyperthermia versus Oncothermia: Cellular Effects in Cancer Therapy

Gyula P. Szigeti,^{1,2} Gabriella Hegyi,³ and Olivér Szasz⁴

¹ Department of Physiology, University of Debrecen, Debrecen 4012, Hungary

² Institute of Human Physiology and Clinical Experimental Research, Semmelweis University, Budapest 1094, Hungary

³ Department of Complementary and Alternative Medicine, University of Pécs, Pécs 7622, Hungary

⁴ Department of Biotechnics, St. Istvan University, Gödöllő 2103, Hungary

Correspondence should be addressed to Gyula P. Szigeti; szigeti.gyulapeter@gmail.com

Received 14 January 2013; Accepted 29 April 2013

Academic Editors: G. F. Baronzio, M. Jackson, and A. Szasz

This Conference Paper is based on a presentation given by Gyula P. Szigeti at “Conference of the International Clinical Hyperthermia Society 2012” held from 12 October 2012 to 14 October 2012 in Budapest, Hungary.

Copyright © 2013 Gyula P. Szigeti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hyperthermia means overheating of the living object completely or partly. Hyperthermia, the procedure of raising the temperature of a part of or the whole body above the normal for a defined period of time, is applied alone or as an adjunctive with various established cancer treatment modalities such as radiotherapy and chemotherapy. The fact that is the hyperthermia is not generally accepted as conventional therapy. The problem is its controversial performance. The controversy is originated from the complications of the deep heating and the focusing of the heat effect. The idea of *oncothermia* solves the selective deep action on nearly cellular resolution. We would like to demonstrate the force and perspectives of oncothermia as a highly specialized hyperthermia in clinical oncology. Our aim is to prove the ability of oncothermia to be a candidate to become a widely accepted modality of the standard cancer care. We would like to show the proofs and the challenges of the hyperthermia and oncothermia applications to provide the presently available data and summarize the knowledge in the topic. Like many early-stage therapies, oncothermia lacks adequate treatment experience and long-range, comprehensive statistics that can help us optimize its use for all indications.

1. Introduction

In oncology, the term “hyperthermia” refers to the treatment of malignant diseases by administering heat in various ways. Hyperthermia is usually applied as an adjunct to an already established treatment modality, where tumor temperatures in the range of 40–46°C are aspired. Interstitial hyperthermia and whole-body hyperthermia are still under clinical investigation, and a few positive comparative trials have already been completed. Parallel to clinical research, several aspects of heat action have been examined in numerous preclinical studies [1–3].

The traditional *hyperthermia* is controlled the only single thermodynamic intensive parameter, with the temperature. *Oncothermia*, which is a “spin-off” form of the hyperthermia, is based on the paradigm of the energy dose control, replacing

the single temperature concept [4]. With this approach, oncothermia returned to the gold standards of the dose concepts in medicine: instead of the parameter, which cannot be regarded as dose (the temperature does not depend on the volume or mass), oncothermia uses the energy (kJ/kg [=Gy]), like the radiation oncology uses the same (Gy) to characterize the dosing of the treatment [5].

2. The Concept of Hyperthermia

The effectiveness of hyperthermia treatment is related to the temperature achieved during the treatment, as well as the length of treatment and cell and tissue characteristics. To ensure that the desired temperature is reached, but not exceeded, the temperature of the tumor and surrounding

tissues is monitored throughout the hyperthermia procedure. The goal is to keep local temperatures under 44°C to avoid damage to surrounding tissues and the whole body temperatures under 42°C, which is the upper limit compatible with life [5].

3. Cellular Mechanisms Induced by Hyperthermia

The cellular effect of hyperthermia is more complicated [6, 7]. Briefly, hyperthermia may kill or weaken tumor cells and is controlled to limit effects on healthy cells. Tumor cells, with a disorganized and compact vascular structure, have difficulty dissipating heat. Hyperthermia may therefore cause cancerous cells to undergo apoptosis in direct response to applied heat, while healthy tissues can more easily maintain a normal temperature. Even if the cancerous cells do not die outright, they may become more susceptible to ionizing radiation therapy or to certain chemotherapy drugs, which may allow such therapy to be given in smaller doses. Intense heating will cause denaturation and coagulation of cellular proteins, rapidly killing cells within the targeted tissue. A mild heat treatment combined with other stresses (excitation of the appropriate signal pathways) can cause cell death by apoptosis.

The potential importance of the hyperthermia for cancer treatment has been highlighted by Coffey et al. [6, 7]. Specifically, the review addresses four topics: (1) hyperthermia-induced cell killing, (2) vascular, (3) cellular and intracellular mechanisms of thermal effects in the hyperthermia temperature range, and (4) effects on proteins that contribute to resistance to other stresses, for example, DNA damage.

(1) *Hyperthermia-Induced Cell Killing*. It has been long recognized that hyperthermia in the 40–47°C temperature range kills cells in a reproducible time- and temperature-dependent manner. In the hyperthermic region, there are three cellular responses for thermal therapy: *cytotoxicity*, *radiosensitization*, and *thermotolerance* [8, 9]. The intensity of cell death in hyperthermia is shown as cell cycle dependence. Both S- and M-phase cells undergo a “slow mode of cell death” after hyperthermia. Cells during G1-phase may follow a “rapid mode of death” immediately after hyperthermia [10–12].

(2) *Vascular*. With higher heat temperatures, there is a corresponding decrease in oxyhemoglobin saturation, and these changes will result in a decrease in overall oxygen availability [13, 14]. This lack of oxygen will also give rise to a decrease in tumor pH and ultimately lead to ischemia and cell death [15]. Normal tissues typically show a very different vascular response to heat, with flow essentially increasing as the temperature increases [16, 17].

(3) *Cellular and Intracellular Mechanisms of Thermal Effects in the Hyperthermia: Cell Metabolism—Hypoxia, pH, ATP, and Its Consequences*. Summarizing the relevant data, it can be stated that tumor temperatures >42.5°C and appropriate heating can reduce both intracellular and extracellular pH,

which may further sensitize tumor cells to hyperthermia in the sense of a positive feedback mechanism [18]. Relevant pathogenic mechanisms leading to an intensified acidosis upon heat treatment (which is reversible after hyperthermia) are as follows:

- (1) an increased glycolytic rate with accumulation of lactic acid,
- (2) an intensified ATP hydrolysis,
- (3) an increased ketogenesis with accumulation of acetoacetic acid and B-hydroxybutyric acid,
- (4) an increase in CO₂ partial pressures,
- (5) changes in chemical equilibria of the intra- and extracellular buffer systems, and
- (6) an inhibition of the Na⁺/H⁺ antiporter in the cell membrane [19, 20].

The ATP decline observed upon heat treatment is mostly due to the following:

- (1) an increased ATP turnover rate (i.e., intensified ATP hydrolysis). As a result of an increased ATP degradation, an accumulation of purine catabolites has to be expected together with a formation of H⁺ ions and reactive oxygen species at several stages during degradation to the final product uric acid,
- (2) a poorer ATP yield as a consequence of a shift from oxidative glucose breakdown to glycolysis [18].

(4) *Effects on Proteins That Contribute to Resistance to Other Stresses, for Example, DNA Damage*. At higher temperatures, inhibition of HSP-synthesis occurs above a distinct threshold temperature. In general, the temperature, respectively, thermal dose at which HSP-synthesis is inhibited in a given experimental system varies between different cell types, but the respective threshold can be lowered when further (proapoptotic) stimuli are added. As lack of HSP-synthesis is associated with exponential cell death, it is generally accepted that HSPs prevent cells from lethal thermal damage. Recently, an additional role has been ascribed to HSPs which should be of importance in hyperthermia as activators of the immune system [21–24].

4. Problems with Hyperthermia

The high energy application could cause controversies: the high temperature burns the malignant cells, but it is missing selectivity. The healthy cells are damaged also, and the hyperthermia starts unwanted physiological reactions as well as enlarged dissemination possibility. These conditions make the hyperthermia effect not controlled.

5. Change of Paradigm: The Concept of Oncothermia

Oncothermia technology heats nonequally, concentrating the absorbed energy to the intercellular electrolytes [25]. This

method creates inhomogeneous heating, microscopic temperature differences far from thermal equilibrium. The definitely large temperature gradient between the intra- and extracellular liquids changes the membrane processes and ignites signal pathways for natural programmed cell death, avoiding the toxic effects of the simple necrosis [25].

Oncothermia works with much less forwarded energy, by focusing energy directly on the malignant tissue using its impedance selectivity even by cellular resolution. This effect is based on the low impedance of the tumor, due to its metabolism, which is higher than that of its healthy counterpart [26].

Based on microscopic effects, there not only the heating which makes the effect but also the electric field itself has a strong synergy with this, having significantly larger cell killing in malignancy at 38°C than the conventional hyperthermia has on 42°C. The process is selective. The radiofrequency current is choosing the “easiest” path to flow, and due to the high ionic concentration of the near neighborhood of malignant cells, the current will be the densest at the tumor cells. The experimental results well support this idea. In the case of healthy cells, the load is equal for all the cells, no difference between the treated and control samples. When we gain the metabolism (immortalized cells) but not yet malignant acceleration, the effect is selectively higher but not significant. However, when the malignancy is present, the cellular growth is aggressive, and the selection becomes effective and kills the tumor cells without affecting the healthy ones in the coculture.

This electric field effect well demonstrates that the average kinetic energy (temperature) has no decisional effect. The main action is the targeted energy delivery, which could be done on such low average energy as the standard healthy body temperature.

6. Cellular Mechanisms Induced by Oncothermia

Clinical oncothermia can induce the following cellular mechanisms.

(1) *Oncothermia Promotes the Programmed Cell Deaths of Tumor.* Detecting the double strains of DNA and measuring the enzymatic labeled strain-breaks of DNA the apoptosis are highly likely in oncothermia [27]. Consequently, the main effect in oncothermia is the apoptosis contrary to the conventional hyperthermia, which operates mainly by necrosis. Investigating the apoptosis by various methods (morphology, beta-catenin relocation, p53 expression, Connexin 43, Tunel, DNA-laddering, etc.), the effects are indicating the same apoptotic process. This process is nontoxic (no inflammatory reactions afterwards), promotes the immune reactions, and does not make processes against those.

(2) *Oncothermia Limits the Dissemination of Malignant Cell.* Oncothermia blocks the tumor cell dissemination, avoiding their motility due to the lazy connections to the tumor. Oncothermia makes it by reestablishing the cellular

connections, which is also great success to save the life. The built up connections could force not only the sticking together but also make bridges between the cells for information exchange to limit the individuality and the competitive behavior of the malignant cells. These are high efficacy factors that favor oncothermia over its temperature-equivalent hyperthermia counterpart. They also produce higher concentration of HSPs in the outer membrane and in the extracellular matrix. The higher HSP concentration in the vicinity of the malignant cells together with the changes of the adherent connections between the cells induces apoptosis. For further information read the longer version of this paper in [28].

Acknowledgment

The authors acknowledge the experimental work and fruitful discussions of Professor Dr. Andras Szasz, Dr. Nora Meggyeshazi, and Dr. Gabor Andocs.

References

- [1] H. R. Moyer and K. A. Delman, “The role of hyperthermia in optimizing tumor response to regional therapy,” *International Journal of Hyperthermia*, vol. 24, no. 3, pp. 251–261, 2008.
- [2] H. Sahinbas, D. H. W. Grönmeyer, E. Böcher, and A. Szasz, “Retrospective clinical study of adjuvant electro-hyperthermia treatment for advanced brain-gliomas,” *Deutsche Zeitschrift für Onkologie*, vol. 39, no. 4, pp. 154–160, 2007.
- [3] B. B. Singh, “Hyperthermia—a new dimension in cancer treatment,” *Indian Journal of Biochemistry and Biophysics*, vol. 27, no. 4, pp. 195–201, 1990.
- [4] A. Szasz, “Physical background and technical realization of hyperthermia,” in *Locoregional Radiofrequency-Perfusional and Wholebody Hyperthermia in Cancer Treatment: New Clinical Aspects*, G. F. Baronzio and E. D. Hager, Eds., pp. 27–59, Springer Science; Eurekah.com, chapter 3, 2006.
- [5] R. B. Roemer, “Engineering aspects of hyperthermia therapy,” *Annual Review of Biomedical Engineering*, vol. 1, pp. 347–376, 1999.
- [6] D. S. Coffey, R. H. Getzenberg, and T. L. Dewese, “Hyperthermic biology and cancer therapies: a hypothesis for the ‘Lance Armstrong effect,’” *Journal of the American Medical Association*, vol. 296, no. 4, pp. 445–448, 2006.
- [7] J. L. Roti, “Cellular responses to hyperthermia (40–46°C): Cell killing and molecular events,” *International Journal of Hyperthermia*, vol. 24, no. 1, pp. 3–15, 2008.
- [8] H. H. Kampinga, J. R. Dynlacht, and E. Dikomey, “Mechanism of radiosensitization by hyperthermia (43°C) as derived from studies with DNA repair defective mutant cell lines,” *International Journal of Hyperthermia*, vol. 20, no. 2, pp. 131–139, 2004.
- [9] A. Laszlo, “The effects of hyperthermia on mammalian cell structure and function,” *Cell Proliferation*, vol. 25, no. 2, pp. 59–87, 1992.
- [10] R. A. Coss, W. C. Dewey, and J. R. Bamburg, “Effects of hyperthermia on dividing Chinese hamster ovary cells and on microtubules in vitro,” *Cancer Research*, vol. 42, no. 3, pp. 1059–1071, 1982.

- [11] K. C. Kregel, "Invited review: heat shock proteins: modifying factors in physiological stress responses and acquired thermo-tolerance," *Journal of Applied Physiology*, vol. 92, no. 5, pp. 2177–2186, 2002.
- [12] A. Westra and W. C. Dewey, "Variation in sensitivity to heat shock during the cell-cycle of Chinese hamster cells in vitro," *International Journal of Radiation Biology and Related Studies in Physics, Chemistry & Medicine*, vol. 19, pp. 467–477, 1971.
- [13] K. Iwata, A. Shakil, W. J. Hur, C. M. Makepeace, R. J. Griffin, and C. W. Song, "Tumour pO₂ can be increased markedly by mild hyperthermia," *British Journal of Cancer*, vol. 74, supplement 27, pp. S217–S221, 1996.
- [14] C. A. Vidair and W. C. Dewey, "Two distinct modes of hyperthermic cell death," *Radiation Research*, vol. 116, no. 1, pp. 157–171, 1988.
- [15] B. Gyldenhof, M. R. Horsman, and J. Overgaard, "Hyperthermia-induced changes in the vascularity and histopathology of a murine tumour and its surrounding normal tissue," in *Hyperthermic Oncology*, C. Franconi, G. Arcangeli, and R. Cavaliere, Eds., vol. 2, pp. 780–782, Tor Vergata, Rome, Italy, 1996.
- [16] P. Vaupel, F. Kallinowski, and P. Okunieff, "Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review," *Cancer Research*, vol. 49, no. 23, pp. 6449–6465, 1989.
- [17] P. W. Vaupel, "Effects of physiological parameters on tissue response to hyperthermia: new experimental facts and their relevance to clinical problems," in *Hyperthermia Oncology*, E. W. Gerner and T. C. Cetas, Eds., pp. 17–23, Tucson Arizona Board of Regents, Tucson, Ariz, USA, 1993.
- [18] P. W. Vaupel and D. K. Kelleher, "Pathophysiological and vascular characteristics of tumours and their importance for hyperthermia: heterogeneity is the key issue," *International Journal of Hyperthermia*, vol. 26, no. 3, pp. 211–223, 2010.
- [19] A. Szentgyorgyi, *Electronic Biology and Cancer*, Marcel Dekker, New York, NY, USA, 1998.
- [20] P. Vaupel and D. K. Kelleher, "Metabolic status and reaction to heat of normal and tumor tissue," in *Thermoradiotherapy and Thermochemotherapy*, M. H. Seegenschmiedt, P. Fessenden, and C. C. Vernon, Eds., vol. 1, pp. 157–176, Springer, New York, NY, USA, 1995.
- [21] B. Hildebrandt, P. Wust, O. Ahlers et al., "The cellular and molecular basis of hyperthermia," *Critical Reviews in Oncology/Hematology*, vol. 43, no. 1, pp. 33–56, 2002.
- [22] H. Kai, M. Ann Suico, S. Morino et al., "A novel combination of mild electrical stimulation and hyperthermia: general concepts and applications," *International Journal of Hyperthermia*, vol. 25, no. 8, pp. 655–660, 2009.
- [23] S. Lindquist, "The heat-shock response," *Annual Review of Biochemistry*, vol. 55, pp. 1151–1191, 1986.
- [24] T. Torigoe, Y. Tamura, and N. Sato, "Heat shock proteins and immunity: application of hyperthermia for immunomodulation," *International Journal of Hyperthermia*, vol. 25, no. 8, pp. 610–616, 2009.
- [25] G. Andocs, H. Renner, L. Balogh, L. Fonyad, C. Jakab, and A. Szasz, "Strong synergy of heat and modulated electromagnetic field in tumor cell killing," *Strahlentherapie und Onkologie*, vol. 185, no. 2, pp. 120–126, 2009.
- [26] G. Andocs, O. Szasz, and A. Szasz, "Oncothermia treatment of cancer: from the laboratory to clinic," *Electromagnetic Biology and Medicine*, vol. 28, no. 2, pp. 148–165, 2009.
- [27] M. E. van Gijn, F. Snel, J. P. M. Cleutjens, J. F. M. Smits, and W. M. Blankesteyn, "Overexpression of components of the Frizzled-Dishevelled cascade results in apoptotic cell death, mediated by β -catenin," *Experimental Cell Research*, vol. 265, no. 1, pp. 46–53, 2001.
- [28] G. Hegyi, G. P. Szigeti, O. Szasz, and A. Szasz, "Hyperthermia versus Oncothermia: cellular effects in cancer therapy," *Evidence-Based Complementary and Alternative Medicine*, vol. 2013, Article ID 672873, 12 pages, 2013.